A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

BACKGROUND: Binimetinib (MEK162; ARRY-438162) is a potent and selective oral MEK 1/2 inhibitor. This phase 1 study determined the maximum tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and preliminary anti-tumour activity of binimetinib in patients with advanced solid tu...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Cancer
Asıl Yazarlar: Bendell, Johanna C, Javle, Milind, Bekaii-Saab, Tanios S, Finn, Richard S, Wainberg, Zev A, Laheru, Daniel A, Weekes, Colin D, Tan, Benjamin R, Khan, Gazala N, Zalupski, Mark M, Infante, Jeffrey R, Jones, Suzanne, Papadopoulos, Kyriakos P, Tolcher, Anthony W, Chavira, Renae E, Christy-Bittel, Janna L, Barrett, Emma, Patnaik, Amita
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2017
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5344293/
https://ncbi.nlm.nih.gov/pubmed/28152546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.10
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller